



Supplementary Material to Olesen et al. “Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study” (Thromb Haemost 2011; 106.4)

Suppl. Figure 1: Hazard ratios of thromboembolism (TE) at 1 year of follow-up. Results from unadjusted time-dependent Cox regression models. ASA: acetylsalicylic acid; CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist.



**Suppl. Figure 2: Hazard ratios of bleeding at one year of follow-up. Results from unadjusted time-dependent Cox regression models. ASA: acetylsalicylic acid; CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist.**



Suppl. Table 1 (a). Rate of thromboembolism per 100 person-years at one year of follow-up (95% confidence interval); according to baseline treatment.

	Years of follow-up	Thromboembolism events	No treatment	VKA	ASA	VKA + ASA
<b>CHADS<sub>2</sub></b>						
Low (score 0)	28,304	449	1.67 (1.47-1.91)	1.31 (1.09-1.57)	2.47 (1.95-3.13)	2.44 (1.73-3.43)
Intermediate (1)	37,226	1,500	3.37 (3.13-3.63)	2.32 (2.06-2.62)	5.36 (4.83-5.94)	2.90 (2.35-3.59)
High (2-6)	45,696	4,663	9.01 (8.67-9.36)	6.93 (6.50-7.38)	12.78 (12.10-13.49)	7.09 (6.41-7.85)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc</b>						
Low (score 0)	11,298	104	1.06 (0.81-1.39)	1.03 (0.75-1.42)	1.36 (0.75-2.45)	0.71 (0.23-2.20)
Intermediate (1)	15,866	265	1.62 (1.37-1.92)	1.28 (1.02-1.61)	2.73 (2.04-3.64)	1.67 (1.04-2.68)
High (2-9)	84,062	6,243	6.77 (6.54-7.00)	4.97 (4.70-5.26)	9.77 (9.31-10.24)	5.83 (5.33-6.38)
<b>Total</b>	<b>111,226</b>	<b>6,612</b>	<b>5.63 (5.45-5.82)</b>	<b>3.92 (3.71-4.14)</b>	<b>8.81 (8.41-9.24)</b>	<b>5.16 (4.72-5.64)</b>

ASA: acetylsalicylic acid; CHADS<sub>2</sub>: see text; CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist

(b). Rate of thromboembolism per 100 person-years at one year of follow-up (95% confidence interval); patients were excluded when they discontinued or changed baseline treatment.

	Years of follow-up	Thromboembolism events	No treatment	VKA	ASA	VKA + ASA
<b>CHADS<sub>2</sub></b>						
Low (score 0)	22,015	332	1.63 (1.40-1.91)	1.32 (1.07-1.63)	2.19 (1.64-2.93)	2.50 (1.69-3.69)
Intermediate (1)	27,616	1,192	3.60 (1.31-3.92)	2.40 (2.09-2.76)	5.71 (5.09-6.41)	3.18 (2.49-4.05)
High (2-6)	33,113	3,774	10.14 (9.72-10.57)	7.71 (7.17-8.28)	14.09 (13.29-14.94)	8.03 (7.17-8.99)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc</b>						
Low (score 0)	9,095	74	1.08 (0.80-1.48)	1.16 (0.82-1.64)	0.81 (0.34-1.95)	0.95 (0.31-2.95)
Intermediate (1)	12,092	186	1.45 (1.18-1.78)	1.21 (0.92-1.59)	2.29 (1.59-3.30)	1.35 (0.73-2.51)
High (2-9)	61,558	5,038	7.56 (7.28-7.84)	5.44 (5.11-5.80)	10.75 (10.21-11.33)	6.58 (5.95-7.28)
Total	82,745	5,298	6.22 (6.00-6.45)	4.22 (3.97-4.49)	9.64 (9.16-10.15)	5.75 (5.21-6.35)

ASA: acetylsalicylic acid; CHADS<sub>2</sub>: see text; CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist

(c). Hazard ratios of thromboembolism at one year of follow-up; according to baseline treatment.

	No treatment	VKA	ASA	VKA + ASA
<b>CHADS<sub>2</sub></b>				
Low (score 0)	1.15 (0.92-1.44)	Reference	1.88 (1.40-2.54)	1.86 (1.27-2.74)
Intermediate (1)	2.07 (1.80-2.38)	Reference	2.28 (1.94-2.67)	1.25 (0.98-1.59)
High (2-6)	1.74 (1.61-1.88)	Reference	1.79 (1.65-1.95)	1.02 (0.90-1.15)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc</b>				
Low (score 0)	0.79 (0.52-1.20)	Reference	1.31 (0.67-2.55)	0.69 (0.21-2.23)
Intermediate (1)	1.34 (1.01-1.79)	Reference	2.12 (1.47-3.07)	1.30 (0.77-2.20)
High (2-9)	1.65 (1.55-1.77)	Reference	1.92 (1.78-2.06)	1.16 (1.05-1.29)

Results from Cox regression analysis. ASA: acetylsalicylic acid; CHADS<sub>2</sub>: see text; CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist

Suppl. Table 2 (a). Rate of bleeding per 100 person-years at one year of follow-up (95% confidence interval); according to baseline treatment.

	Years of follow-up	Bleeding events	No treatment	VKA	ASA	VKA + ASA
<b>CHADS<sub>2</sub></b>						
Low (score 0)	28,087	804	3.15 (2.86-3.47)	2.69 (2.37-3.06)	3.65 (3.01-4.44)	5.11 (4.03-6.48)
Intermediate (1)	36,888	1,953	5.17 (4.87-5.49)	4.55 (4.17-4.96)	5.77 (5.21-6.38)	6.20 (5.35-7.18)
High (2-6)	45,910	3,126	6.72 (6.43-7.03)	5.91 (5.51-6.33)	6.95 (6.46-7.47)	8.42 (7.67-9.25)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc</b>						
Low (score 0)	11,223	222	2.19 (1.81-2.65)	1.91 (1.51-2.42)	2.87 (1.91-4.32)	3.37 (1.99-5.68)
Intermediate (1)	15,729	512	3.27 (2.91-3.69)	2.95 (2.53-3.43)	3.47 (2.68-4.49)	4.78 (3.60-6.35)
High (2-9)	83,934	5,149	6.18 (5.96-6.40)	5.41 (5.13-5.71)	6.49 (6.12-6.89)	7.80 (7.21-8.43)
<b>Total</b>	<b>110,885</b>	<b>5,883</b>	<b>5.48 (5.30-5.67)</b>	<b>4.62 (4.39-4.85)</b>	<b>6.09 (5.75-6.44)</b>	<b>7.28 (6.76-7.85)</b>

ASA: acetylsalicylic acid; CHADS<sub>2</sub>: see text; CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist

(b). Rate of bleeding per 100 person-years at one year of follow-up (95% confidence interval); patients were excluded when they discontinued or changed baseline treatment.

	Years of follow-up	Bleeding events	No treatment	VKA	ASA	VKA + ASA
<b>CHADS<sub>2</sub></b>						
Low (score 0)	21,846	612	3.18 (2.84-3.56)	2.72 (2.35-3.16)	3.47 (2.75-4.37)	5.59 (4.29-7.28)
Intermediate (1)	27,332	1,481	5.45 (5.09-5.84)	4.80 (4.35-5.31)	6.05 (5.41-6.78)	6.52 (5.49-7.73)
High (2-6)	33,146	2,352	7.14 (6.79-7.50)	6.28 (5.80-6.80)	7.25 (6.68-7.86)	9.15 (8.22-10.18)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc</b>						
Low (score 0)	9,033	170	2.24 (1.80-2.78)	1.86 (1.41-2.45)	2.79 (1.74-4.49)	4.53 (2.68-7.64)
Intermediate (1)	11,984	378	3.26 (2.84-3.75)	2.95 (2.47-3.52)	3.68 (2.75-4.91)	4.38 (3.10-6.19)
High (2-9)	61,307	3,897	6.55 (6.29-6.82)	5.77 (5.42-6.14)	6.75 (6.32-7.21)	8.46 (7.74-9.26)
Total	82,324	4,445	5.77 (5.55-5.99)	4.84 (4.57-5.12)	6.33 (5.95-6.75)	7.84 (7.19-8.54)

ASA: acetylsalicylic acid; CHADS<sub>2</sub>: see text; CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist

(c). Hazard ratios of bleeding at one year of follow-up; according to baseline treatment.

	No treatment	VKA	ASA	VKA + ASA
<b>CHADS<sub>2</sub></b>				
Low (score 0)	0.97 (0.82-1.13)	Reference	1.34 (1.06-1.69)	1.88 (1.44-2.46)
Intermediate (1)	1.18 (1.06-1.32)	Reference	1.25 (1.09-1.42)	1.35 (1.14-1.61)
High (2-6)	1.16 (1.06-1.27)	Reference	1.15 (1.04-1.27)	1.42 (1.26-1.59)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc</b>				
Low (score 0)	0.94 (0.70-1.27)	Reference	1.48 (0.92-2.36)	1.75 (0.99-3.11)
Intermediate (1)	1.09 (0.89-1.33)	Reference	1.16 (0.86-1.57)	1.61 (1.17-2.22)
High (2-9)	1.11 (1.03-1.19)	Reference	1.18 (1.09-1.27)	1.43 (1.30-1.57)

Results from Cox regression analysis. ASA: acetylsalicylic acid; CHADS<sub>2</sub>: see text; CHA<sub>2</sub>DS<sub>2</sub>-VASc: see text; VKA: vitamin K antagonist